279 related articles for article (PubMed ID: 24989117)
1. Elevation of striatal urate in experimental models of Parkinson's disease: a compensatory mechanism triggered by dopaminergic nigrostriatal degeneration?
De Luca MA; Cauli O; Morelli M; Simola N
J Neurochem; 2014 Nov; 131(3):284-9. PubMed ID: 24989117
[TBL] [Abstract][Full Text] [Related]
2. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
[TBL] [Abstract][Full Text] [Related]
3. Effects of testosterone upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system of C57/B1 mice.
Dluzen DE
Brain Res; 1996 Apr; 715(1-2):113-8. PubMed ID: 8739629
[TBL] [Abstract][Full Text] [Related]
4. Progression and recovery of Parkinsonism in a chronic progressive MPTP-induction model in the marmoset without persistent molecular and cellular damage.
Franke SK; van Kesteren RE; Wubben JA; Hofman S; Paliukhovich I; van der Schors RC; van Nierop P; Smit AB; Philippens IH
Neuroscience; 2016 Jan; 312():247-59. PubMed ID: 26431624
[TBL] [Abstract][Full Text] [Related]
5. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine hydroxylase expression and activity in nigrostriatal dopaminergic neurons of MPTP-treated mice at the presymptomatic and symptomatic stages of parkinsonism.
Kozina EA; Khakimova GR; Khaindrava VG; Kucheryanu VG; Vorobyeva NE; Krasnov AN; Georgieva SG; Kerkerian-Le Goff L; Ugrumov MV
J Neurol Sci; 2014 May; 340(1-2):198-207. PubMed ID: 24768159
[TBL] [Abstract][Full Text] [Related]
7. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections.
Kozlowski DA; Connor B; Tillerson JL; Schallert T; Bohn MC
Exp Neurol; 2000 Nov; 166(1):1-15. PubMed ID: 11031079
[TBL] [Abstract][Full Text] [Related]
8. Adaptive changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse.
Bezard E; Jaber M; Gonon F; Boireau A; Bloch B; Gross CE
Eur J Neurosci; 2000 Aug; 12(8):2892-900. PubMed ID: 10971632
[TBL] [Abstract][Full Text] [Related]
9. Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson's disease.
Andringa G; Drukarch B; Bol JG; de Bruin K; Sorman K; Habraken JB; Booij J
Neuroimage; 2005 Jul; 26(4):1150-8. PubMed ID: 15908232
[TBL] [Abstract][Full Text] [Related]
10. Admixing of MPTP-Resistant and Susceptible Mice Strains Augments Nigrostriatal Neuronal Correlates to Resist MPTP-Induced Neurodegeneration.
Vidyadhara DJ; Yarreiphang H; Raju TR; Alladi PA
Mol Neurobiol; 2017 Oct; 54(8):6148-6162. PubMed ID: 27704331
[TBL] [Abstract][Full Text] [Related]
11. Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.
Rojo AI; Cavada C; de Sagarra MR; Cuadrado A
Exp Neurol; 2007 Nov; 208(1):120-6. PubMed ID: 17880941
[TBL] [Abstract][Full Text] [Related]
12. FGF-2 in the MPTP model of Parkinson's disease: effects on astroglial cells.
Otto D; Unsicker K
Glia; 1994 May; 11(1):47-56. PubMed ID: 8070894
[TBL] [Abstract][Full Text] [Related]
13. Alteration of dopaminergic markers in gastrointestinal tract of different rodent models of Parkinson's disease.
Tian YM; Chen X; Luo DZ; Zhang XH; Xue H; Zheng LF; Yang N; Wang XM; Zhu JX
Neuroscience; 2008 May; 153(3):634-44. PubMed ID: 18420351
[TBL] [Abstract][Full Text] [Related]
14. Heat shock protein 70 kDa over-expression and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigrostriatal degeneration in mice.
Gao L; Díaz-Martín J; Dillmann WH; López-Barneo J
Neuroscience; 2011 Oct; 193():323-9. PubMed ID: 21782904
[TBL] [Abstract][Full Text] [Related]
15. GDNF Overexpression from the Native Locus Reveals its Role in the Nigrostriatal Dopaminergic System Function.
Kumar A; Kopra J; Varendi K; Porokuokka LL; Panhelainen A; Kuure S; Marshall P; Karalija N; Härma MA; Vilenius C; Lilleväli K; Tekko T; Mijatovic J; Pulkkinen N; Jakobson M; Jakobson M; Ola R; Palm E; Lindahl M; Strömberg I; Võikar V; Piepponen TP; Saarma M; Andressoo JO
PLoS Genet; 2015 Dec; 11(12):e1005710. PubMed ID: 26681446
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of microglial C1q expression has no effects on nigrostriatal dopaminergic injury in the MPTP mouse model of Parkinson disease.
Depboylu C; Schorlemmer K; Klietz M; Oertel WH; Weihe E; Höglinger GU; Schäfer MK
J Neuroimmunol; 2011 Jul; 236(1-2):39-46. PubMed ID: 21640391
[TBL] [Abstract][Full Text] [Related]
17. The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration.
Drouin-Ouellet J; Gibrat C; Bousquet M; Calon F; Kriz J; Cicchetti F
J Neuroinflammation; 2011 Oct; 8():137. PubMed ID: 21989292
[TBL] [Abstract][Full Text] [Related]
18. Tanshinone IIA prevents the loss of nigrostriatal dopaminergic neurons by inhibiting NADPH oxidase and iNOS in the MPTP model of Parkinson's disease.
Ren B; Zhang YX; Zhou HX; Sun FW; Zhang ZF; Wei Z; Zhang CY; Si DW
J Neurol Sci; 2015 Jan; 348(1-2):142-52. PubMed ID: 25491263
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease.
Watanabe Y; Himeda T; Araki T
Med Sci Monit; 2005 Jan; 11(1):RA17-23. PubMed ID: 15614202
[TBL] [Abstract][Full Text] [Related]
20. Neurotrophic and neurorescue effects of Echinacoside in the subacute MPTP mouse model of Parkinson's disease.
Zhao Q; Gao J; Li W; Cai D
Brain Res; 2010 Jul; 1346():224-36. PubMed ID: 20478277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
